These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 31338986)

  • 1. Risk of opportunistic infections in patients with antineutrophil cytoplasmic antibody-associated vasculitis, using a Japanese health insurance database.
    Sakai R; Tanaka E; Nishina H; Suzuki M; Yamanaka H; Harigai M
    Int J Rheum Dis; 2019 Nov; 22(11):1978-1984. PubMed ID: 31338986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for cytomegalovirus infection in patients with antineutrophil cytoplasmic antibody-associated vasculitis.
    Morishita M; Sada KE; Matsumoto Y; Hayashi K; Asano Y; Hiramatsu Asano S; Ohashi K; Miyawaki Y; Katsuyama E; Watanabe H; Kawabata T; Wada J
    PLoS One; 2019; 14(7):e0218705. PubMed ID: 31291263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial high-dose corticosteroids and renal impairment are risk factors for early severe infections in elderly patients with antineutrophil cytoplasmic autoantibody-associated vasculitis: A retrospective observational study.
    Waki D; Nishimura K; Tokumasu H; Kadoba K; Mukoyama H; Saito R; Murabe H; Yokota T
    Medicine (Baltimore); 2020 Feb; 99(8):e19173. PubMed ID: 32080098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial.
    Sanders JS; de Joode AA; DeSevaux RG; Broekroelofs J; Voskuyl AE; van Paassen P; Kallenberg CG; Tervaert JW; Stegeman CA
    Nephrol Dial Transplant; 2016 Sep; 31(9):1453-9. PubMed ID: 27242368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors correlated with immunosuppressant discontinuation in antineutrophil cytoplasmic antibody-associated vasculitis patients.
    Murosaki T; Sato T; Nagatani K; Sato K; Minota S
    Int J Rheum Dis; 2020 Nov; 23(11):1587-1593. PubMed ID: 32996696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential Therapy for Remission Induction in Severe Antineutrophil Cytoplasmic Autoantibody-Associated Glomerulonephritis.
    Kant S; Habbach A; Gapud EJ; Manno RL; Gattu R; Seo P; Geetha D
    Am J Nephrol; 2019; 50(5):386-391. PubMed ID: 31593967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical characteristics of and risk factors for serious infection in Japanese patients within six months of remission induction therapy for antineutrophil cytoplasmic antibody-associated vasculitis registered in a nationwide, prospective, inception cohort study.
    Watanabe-Imai K; Harigai M; Sada KE; Yamamura M; Fujii T; Dobashi H; Amano K; Ito S; Homma S; Kumagai S; Banno S; Arimura Y; Makino H;
    Mod Rheumatol; 2017 Jul; 27(4):646-651. PubMed ID: 27538706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experience with seven Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis treated with remission-induction therapy with intravenous cyclophosphamide according to the CYCLOPS protocol.
    Oiwa H; Yamasaki S; Endo K; Nojima T; Kumagai K; Sugiyama E
    Intern Med; 2014; 53(20):2291-6. PubMed ID: 25318790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study.
    Jayne D; Blockmans D; Luqmani R; Moiseev S; Ji B; Green Y; Hall L; Roth D; Henderson RB; Merkel PA;
    Arthritis Rheumatol; 2019 Jun; 71(6):952-963. PubMed ID: 30666823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety and efficacy of rituximab in 7 Japanese patients with ANCA-associated vasculitis.
    Nagafuchi H; Atsumi T; Hatta K; Muso E; Takeno M; Yamada H; Ozaki S
    Mod Rheumatol; 2015 Jul; 25(4):603-8. PubMed ID: 25496405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclophosphamide followed by rituximab for aggressive multiple-relapsing antineutrophil cytoplasmic antibody-associated vasculitis.
    Lionaki S; Fragoulis GE; Venetsanopoulou A; Vlachoyiannopoulos P; Boletis JN; Tzioufas AG
    Clin Exp Rheumatol; 2017; 35 Suppl 103(1):155-164. PubMed ID: 28134075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for infectious complications of ANCA-associated vasculitis: a cohort study.
    Yang L; Xie H; Liu Z; Chen Y; Wang J; Zhang H; Ge Y; Hu W
    BMC Nephrol; 2018 Jun; 19(1):138. PubMed ID: 29902982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated Vasculitis: a multi-center retrospective cohort study.
    Chanouzas D; McGregor JAG; Nightingale P; Salama AD; Szpirt WM; Basu N; Morgan MD; Poulton CJ; Draibe JB; Krarup E; Dospinescu P; Dale JA; Pendergraft WF; Lee K; Egfjord M; Hogan SL; Harper L
    BMC Nephrol; 2019 Feb; 20(1):58. PubMed ID: 30777023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk Factors for Relapse of Antineutrophil Cytoplasmic Antibody-associated Vasculitis in Japan: A Nationwide, Prospective Cohort Study.
    Hara A; Wada T; Sada KE; Amano K; Dobashi H; Harigai M; Takasaki Y; Yamada H; Hasegawa H; Hayashi T; Fujimoto S; Muso E; Kawakami T; Homma S; Yoshida M; Hirahashi J; Ogawa N; Ito S; Makino H; Arimura Y;
    J Rheumatol; 2018 Apr; 45(4):521-528. PubMed ID: 29419469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial.
    Gopaluni S; Smith RM; Lewin M; McAlear CA; Mynard K; Jones RB; Specks U; Merkel PA; Jayne DR;
    Trials; 2017 Mar; 18(1):112. PubMed ID: 28270229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral candidiasis is a significant predictor of subsequent severe infections during immunosuppressive therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis.
    Yamaguchi M; Katsuno T; Iwagaitsu S; Nobata H; Kinashi H; Banno S; Ito Y
    BMC Infect Dis; 2019 Jul; 19(1):664. PubMed ID: 31349802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents.
    Lenert A; Lenert P
    Drug Des Devel Ther; 2015; 9():333-47. PubMed ID: 25609919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The CD4 Lymphocyte Count is a Better Predictor of Overall Infection Than the Total Lymphocyte Count in ANCA-Associated Vasculitis Under a Corticosteroid and Cyclophosphamide Regimen: A Retrospective Cohort.
    Shi YY; Li ZY; Zhao MH; Chen M
    Medicine (Baltimore); 2015 May; 94(18):e843. PubMed ID: 25950695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.
    Smith RM; Jones RB; Guerry MJ; Laurino S; Catapano F; Chaudhry A; Smith KG; Jayne DR
    Arthritis Rheum; 2012 Nov; 64(11):3760-9. PubMed ID: 22729997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with cytomegalovirus infection in antineutrophil cytoplasmic antibody-associated vasculitis: A narrative review.
    Leong A; Fong W
    Int J Rheum Dis; 2022 Dec; 25(12):1357-1367. PubMed ID: 36135777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.